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OBJECTIVE—Podocyte-speciﬁc, doxycycline (DOX)-inducible
overexpression of soluble vascular endothelial growth factor
(VEGF) receptor-1 (sFlt-1) in adult mice was used to investigate
the role of the VEGF-A/VEGF receptor (VEGFR) system in
diabetic glomerulopathy.
RESEARCH DESIGN AND METHODS—We studied nondia-
betic and diabetic transgenic mice and wild-type controls treated
with vehicle (VEH) or DOX for 10 weeks. Glycemia was mea-
sured by a glucose-oxidase method and blood pressure by a
noninvasive technique. sFlt-1, VEGF-A, VEGFR2, and nephrin
protein expression in renal cortex were determined by Western
immunoblotting; urine sFlt-1, urine free VEGF-A, and albumin-
uria by enzyme-linked immunosorbent assay; glomerular ultra-
structure by electron microscopy; and VEGFR1 and VEGFR2
cellular localization with Immunogold techniques.
RESULTS—Nondiabetic DOX-treated transgenic mice showed a
twofold increase in cortex sFlt-1 expression and a fourfold
increase in sFlt-1 urine excretion (P  0.001). Urine free VEGF-A
was decreased by 50%, and cortex VEGF-A expression was
upregulated by 30% (P  0.04). VEGFR2 expression was un-
changed, whereas its activation was reduced in DOX-treated
transgenic mice (P  0.02). Albuminuria and glomerular mor-
phology were similar among groups. DOX-treated transgenic
diabetic mice showed a 60% increase in 24-h urine sFlt-1 excre-
tion and an 70% decrease in urine free VEGF-A compared with
VEH-treated diabetic mice (P  0.04) and had lower urine
albumin excretion at 10 weeks than VEH-treated diabetic (D)
mice: D-VEH vs. D-DOX, geometric mean (95% CI), 117.5 (69–199)
vs. 43 (26.8–69) g/24 h (P  0.003). Diabetes-induced mesangial
expansion, glomerular basement membrane thickening, podo-
cyte foot-process fusion, and transforming growth factor-1
expression were ameliorated in DOX-treated diabetic animals
(P  0.05). Diabetes-induced VEGF-A and nephrin expression
were not affected in DOX-treated mice.
CONCLUSIONS—Podocyte-speciﬁc sFlt-1 overexpression ame-
liorates diabetic glomerular injury, implicating VEGF-A in the
pathogenesis of this complication. Diabetes 57:2824–2833,
2008
V
ascular endothelial growth factor (VEGF)-A is
constitutively expressed in glomerular visceral
cells (podocytes). Paracrine VEGF-A signaling
occurs between podocytes and adjacent endothe-
lial and mesangial cells, which express VEGF receptors
(VEGFRs) 1 and 2 (1–3), and both autocrine and paracrine
signaling may occur in podocytes themselves (4).
VEGF-A has been implicated in the regulation of glomer-
ular barrier properties to protein ﬁltration. In normal
animals (5,6) and in cancer patients (7), inhibition of
VEGF-A results in proteinuria; while in proteinuric condi-
tions, which are associated with glomerular VEGF-A up-
regulation such as diabetes, systemic inhibition of VEGF
ameliorates albuminuria (8–10). This evidence suggests
that a tight regulation of VEGF-A expression level is
required to maintain the physiological permselective prop-
erties of the glomerular ﬁlter.
The results of previous studies conducted using either
VEGF gene targeting techniques (5) or by administration
of inhibitory agents of the VEGF/VEGFR system such as
antibodies (6,8,9) or chemicals (10) may have been af-
fected by potential interference with animal organ devel-
opment and lack of tissue speciﬁcity in the mechanisms of
action of systemic inhibitors. Soluble VEGF receptor-1
(sFlt-1), a splice variant of the VEGFR1, lacks the trans-
membrane and complete intracellular tyrosine kinase do-
main of VEGFR1 but binds to VEGF with the same afﬁnity
and speciﬁcity as that of the full-length receptor (11,12)
and has potent and selective VEGF inhibitory action (11).
sFlt-1 acts in two major ways: it can sequester VEGF
competing for its binding to the VEGF receptors or can
form heterodimers with the extracellular region of the
membrane spanning VEGFR1 and VEGFR2, thus inhibiting
the activation of downstream signaling pathways (11,12).
To target the action of the podocyte-expressed VEGF-A,
we developed a transgenic mouse model to overexpress
sFlt-1 speciﬁcally at the podocyte level with an inducible
expression system that is induced only after complete
development, in the adult animal, by the administration of
doxycycline (Tet-on). The aim of this study was to inves-
tigate the role of VEGF-A upregulation in the pathogenesis
of diabetic glomerulopathy by locally inhibiting podocyte-
expressed VEGF-A activity.
RESEARCH DESIGN AND METHODS
All materials and chemicals were purchased from Sigma-Aldrich (Dorset,
U.K.). Restriction endonucleases were obtained from Fermentas (St. Leon-
Rot, Germany), and the DNA ligase kit was from Roche Applied Science
(Sussex, U.K.).
Generation of transgenic animals. Construct generation (tetracycline
reponsive element [TRE] construct): Human sFlt-1 cDNA was obtained from
the plasmid pbb-sFlt-1 (gift from Dr. K.A. Thomas) (12) by BamHI restriction
endonuclease digestion. The obtained cDNA was then cloned into the plasmid
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2824 DIABETES, VOL. 57, OCTOBER 2008pBI-G Tet-Vector (GenBank accession no. U89933) (Takara Bio Europe/
Clontech, Saint-Germain-en-Laye, France). The resulting plasmid, pTRE bidi-
rectional LacZ/sFlt-1, was studied for the presence and orientation of the
insert (sFlt-1 cDNA) in the ﬁnal vector by restriction endonuclease digestion.
The 8-kb AsnI-AsnI DNA fragment was utilized for microinjection and
generation of transgenic animals.
Generation of transgenic mice. Transgenic mice were generated in the
Transgenic Facility of the Medical Research Council, Imperial College
London.
Animals were kept according to the “Guidelines on the Use of Animals in
Research,” and the number of utilized animals was kept to a minimum. Mice
were housed in a pathogen-free environment at 21°C, with a 12-h light-dark
cycle, and all received a standard laboratory animal diet (Beekey Feeds) and
water ad libitum.
Animal genotyping. Transgene genomic integration was initially studied
using standard Southern blotting technique. Subsequently, mice were geno-
typed by PCR as described (13). For the “pTRE bidirectional LacZ/sFlt-1”
plasmid, we used the following set of primers recognizing the 3-sv40 poly-A
DNA sequence: sense 5-ACCTATAAAAATAGGCGTATCACGA-3, antisense
5-TGGCTGATTATGATCCTGCA-3. The genotyping for the podocin-rtTA was
also studied using PCR, as previously described (14).
Induction of podocyte sFlt-1 overexpression in transgenic mice. Exper-
iments were conducted in mice obtained from the breeding of homozygous
Podocin-rtTA mice (Pod/Pod) with heterozygous pTRE-LacZ/sFlt-1 (sFlt-1/)
mice in order to obtain litters containing animals heterozygous for both
constructs (Pod/sFlt-1). Expression of sFlt-1 was induced in mice by the
administration of doxycycline (DOX) (2 mg/ml) in the drinking water as
previously shown (13). Water was supplemented with sucrose (5% wt/vol)
(abbreviated as vehicle [VEH]) to enhance palatability. Doxycycline was
replaced every 3rd day and protected from light at all time. Controls were
given VEH alone.
X-gal staining. Standard histochemical detection of nuclear -galactosidase
activity was determined as previously described (13).
sFlt-1 expression. sFlt-1 protein levels were assessed by Western immuno-
blotting techniques in kidney cortex lysate and by enzyme-linked immunosor-
bent assay (ELISA) in 24-h urine collection.
Experimental design and determinations. Experiments were conducted in
8-week-old nondiabetic or diabetic control mice (Pod/, only positive for the
Podocin-rtTA transgene) and double heterozygote Pod/sFlt-1 mice either
administered VEH or treated with DOX for up to 10 weeks.
Twenty four–hour urine collections for each animal (in individual meta-
bolic cages) were made at baseline (8-week-old mice, before DOX adminis-
tration), between 6 and 8 weeks later, and then 10 weeks thereafter. At the end
of the study, mice were weighed and killed, and the cortex was isolated for
protein molecular determinations and electron microscopy studies.
Streptozotocin-induced diabetes in transgenic mice. Diabetes was in-
duced in 5-week-old mice with daily intraperitoneal streptozotocin injec-
tions for 5 days as previously described (15). Control mice were injected with
citrate buffer only. After 2 weeks, diabetes was veriﬁed by blood glucose
determination with the glucose oxidase method. Mice with a glycemia 22
mmol/l were not included in the study.
Blood pressure. Systolic blood pressure was measured from the mouse tail
with a CODA noninvasive pletismography blood pressure transducer (Kent
Scientiﬁc).
Creatinine clearance. Blood samples were collected using heparinized
tubes via cardiac puncture at the time of killing of the animals. Urine was
collected as detailed above. Plasma and urine creatinine concentration was
determined by isotope dilution electrospray mass spectrometry (16). Creati-
nine clearance (l  min
1  g
1) was estimated as urinary creatinine 	 urine
volume 	 1,440 min
1 	 plasma creatinine
1 	 body wt (g)
1.
Urine albumin excretion. Urine volume was recorded and aliquots (1 ml)
were stored at 80°C for subsequent analysis. Albumin concentration in urine
was measured in triplicate by ELISA using an anti-mouse albumin antibody
(Bethyl Laboratories, Montgomery, TX). Urine albumin excretion was ex-
pressed as the 24-h albumin excretion rate (in micrograms per 24 h).
Urine free VEGF-A and sFlt-1 levels. Urine samples were collected and
immediately centrifuged at 13,000g for 5 min, then stored at 80°C. A
commercial ELISA kit was used to measure free VEGF-A165 (R&D Systems
Europe, Abingdon, U.K.). This assay speciﬁcally measures unbound VEGF-A
and does not crossreact with VEGF-A bound to sFlt-1. Another ELISA was
used to speciﬁcally measure sFlt-1 (RELIATech, Braunschweig, Germany)
(17,18). For both determinations, assays were conducted in duplicate and
results expressed as picograms per 24 h for VEGF-A165 and as nanograms per
24 h for sFlt-1.
Western blotting. The following antibodies (and dilutions) were used: rabbit
monoclonal anti–sFlt-1 (1:500) (Sigma-Aldrich), rabbit polyclonal anti-nephrin
intracellular domain (1:500) (donated by H. Holthofer, Helsinki University,
Finland), goat anti-mouse VEGF-A (1:250) (R&D Systems), rat anti-VEGFR2
(1:250) (R&D Systems), rabbit anti-VEGFR2[pY (951)] (1:500) (BioSource,
Nivelles, Belgium), rabbit polyclonal anti–transforming growth factor (TGF)-
receptor2 (1:400) (Santa Cruz Biotech, Santa Cruz, CA), rabbit polyclonal
anti-TGF1 (1:400) (Santa Cruz Biotech), and anti–-actin (1:5,000) (Sigma-
Aldrich).
Pieces of renal cortex were lysed in modiﬁed RIPA buffer containing
protease and phosphatase inhibitor cocktail (Sigma-Aldrich). Equal amounts
of total protein lysate (40–200 g) were run on 7.5 or 10% SDS-polyacrylamide
denaturing gels and transferred to nitrocellulose membranes (Amersham
Biosciences, Little Chalfont, U.K.). The membranes were incubated in 5%
nonfat milk or 3% bovine serum albumin and 0.1% Tween in PBS for3ha t
room temperature for sFlt-1, VEGF-A, nephrin, VEGFR2, TGF-receptor2,
TGF1, -actin, and VEGFR2[pY (951)] antibodies. Membranes were subse-
quently probed with speciﬁc horseradish peroxidase–conjugated secondary
antibodies (1:5,000–10,000) (Dako) for1ha troom temperature. Bands were
revealed using an enhanced chemiluminescence kit (Amersham Biosciences).
Quantiﬁcation of the immunoreactive bands was performed using densitomet-
ric scanning with image software (Image J; National Institute of Health,
Bethesda, MD).
Glomerular morphology. Mesangial volume fraction, as an index of glomer-
ular extracellular matrix deposition, glomerular basement membrane (GBM)
thickening, podocyte foot process width (FPW), and glomerular capillaries
endothelial fenestrae were studied with electron microscopy techniques as
previously described (19).
Glomerular cell VEGF receptor expression. The Immunogold electron
microscopy technique was used to study the presence of VEGF receptors on
glomerular cells in both nondiabetic and diabetic mice. Pieces of cortical
tissue 1 mm
3 in size were ﬁxed in 2% paraformaldehyde for 4 h, dehydrated in
alcohol, and embedded in LR-white resin (TAAB). Ultrathin sections were
taken and mounted on carbon-coated nickel grids. The grids were ﬁrst
immersed in 80 mmol/l ammonium chloride in PBS (10 min), then in PBS
containing 0.2 mol/l glycine and 0.5% BSA (10 min), followed by 10% normal
rat serum for 30 min, all at room temperature. The grids were then incubated
with primary antibody (rabbit anti-mouse VEGFR1 and VEGFR2; Abcam)
diluted 1:100 in PBS/0.5% BSA overnight at 4°C. After washing in PBS/0.5%
BSA, the grids were incubated with 10 nm gold-conjugated goat anti-rabbit IgG
diluted 1:20 in PBS/0.5% BSA for1ha troom temperature. The primary
antibody was omitted in negative controls. After washing, the grids were
stained with 2% aqueous uranyl acetate and examined by transmission
electron microscopy.
Statistics. Results are expressed as the mean 
 SEM unless otherwise stated.
Data for albuminuria were log transformed before analysis. Among-group
comparisons were performed by ANOVA followed by post hoc analysis for
between-group differences using the least signiﬁcant difference test. P  0.05
was considered statistically signiﬁcant.
RESULTS
Generation of transgenic mice. We obtained eight pos-
itive founders for the pTRE bidirectional LacZ/sFlt-1 con-
struct. Seven of eight founders transmitted the transgene
to the offspring. Mice derived from the F1 generation were
then bred with FVB-N mice homozygous for the construct
podocin-rtTA (gift from Dr. J. Kopp, Bethesda, MD) ex-
pressing the rtTA speciﬁcally in podocytes (14). First-
generation offspring carrying either both transgenes or
podocin rtTA only (mixed background BL6-CBA/FVB-N,
abbreviated to Pod/sFlt1 and Pod/ as controls) were
studied for DOX-inducible transgene expression. Of these
seven remaining lines, one showed a DOX-inducible LacZ
(nuclear localization) expression in podocytes with no
basal leaky expression of the transgene and was subse-
quently used in all experiments.
Role of podocyte sFlt-1 overexpression in adult con-
trol, nondiabetic mice. Eight-week-old adult double
transgenic mice (Pod/sFlt-1) or single transgenic mice
(Pod/) were treated with DOX or administered VEH for
up to 10 weeks (both sexes showed a similar phenotype
and were analyzed together). X-gal staining revealed no
signal in Pod/ DOX and VEH kidneys, conﬁrming that the
staining protocol did not detect endogenous galactosidase
activity (not shown). Furthermore, Pod/sFlt-1 mice admin-
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1A), excluding “leakage” of LacZ expression in nonin-
duced mice. In contrast, kidneys from adult Pod/sFlt-1
mice exposed to DOX showed positive X-gal staining (Fig.
1A), consistent with podocyte expression of the transgene
(13,14). X-gal staining was analyzed at different time points
after DOX administration (10 days, 5–10 weeks), and the
results were superimposable (not shown). After 10 weeks
of treatment with DOX, Pod/sFlt-1 animals showed a
signiﬁcant inducible sFlt-1 overexpression (100% increase)
when assessed in kidney cortex lysate (Fig. 1B). The
upregulation of sFlt-1 was associated with an increase in
24-h urine sFlt-1 levels, which was four- to ﬁvefold higher
in DOX-treated Pod/sFlt-1 compared with Pod/sFlt-1 mice
given VEH or with Pod/ control mice (P  0.001) (Fig.
2A). This was paralleled by a reduction in urine free VEGF-A
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FIG. 1. Podocyte-inducible overexpression of LacZ/sFlt-1. A: Nu-
clear LacZ staining of glomerular podocytes was detected in
DOX-treated but not in VEH-administered double transgenic mice
(10 weeks of treatment). No staining was observed in Pod/
administered VEH or DOX (not shown). B: Densitometry quanti-
tative analysis of sFlt-1 expression (as a ratio with -actin) in
total kidney cortex lysate after 10 weeks of treatment with VEH
or DOX. Data are expressed as mean  SEM (*P < 0.01 for
Pod/sFlt-1 DOX vs. all other groups, P  NS for Pod/ VEH vs.
Pod/ DOX; n  4–8/group). (Please see http://dx.doi.org/10.2337/
db08-0647 for a high-quality digital representation of this ﬁgure.)
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FIG. 2. sFlt-1 and VEGF-A 24-h urine excretion, VEGF-A expression, and VEGFR2 phosphorylation in renal cortex in podocyte-speciﬁc sFlt-1
overexpressing mice after 10 weeks of treatment with VEH or DOX. A: Urine sFlt-1 excretion was signiﬁcantly increased in Pod/sFlt-1
DOX-treated mice (*P < 0.001 for Pod/sFlt-1 DOX vs. all other groups, P  NS for Pod/ VEH vs. Pod/ DOX; n  6–10/group). B: 24-h urine free
VEGF-A excretion was signiﬁcantly reduced in Pod/sFlt-1 DOX-treated mice (*P < 0.04 for Pod/sFlt-1 DOX vs. all other groups, P  NS for Pod/
VEH vs. Pod/ DOX; n  5–10/group). C: By densitometry, quantitative analysis of renal cortex showing that VEGF-A protein expression was
signiﬁcantly upregulated in Pod/sFlt-1 DOX-treated mice (*P < 0.03 for Pod/sFlt-1 DOX vs. all other groups, P  NS for Pod/ VEH vs. Pod/ DOX;
n  5–6/group). D: The ratio of phosphorylated [Tyr(951)] VEGFR2 over total VEGFR2 was downregulated in Pod/sFlt-1 DOX-treated mice (*P <
0.01 for Pod/sFlt-1 DOX vs. all other groups, P  NS for Pod/ VEH vs. Pod/ DOX; n  4–8/group).
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ated “sequestration/binding” of VEGF-A (P  0.04) (Fig. 2B).
Renal cortex VEGF-A was upregulated in Pod/sFlt-1 DOX
mice in comparison with the other groups (P  0.03) (Fig.
2C). No difference was observed in the renal cortex expres-
sion levels of VEGFR2 among the groups of mice studied
(Pod/ VEH, 1.5 
 0.3; Pod/ DOX, 1.7 
 0.3; Pod/sFlt-1
VEH, 1.7 
 0.3; Pod/sFlt-1 DOX, 1.5 
 0.2 VEGF-R2/-actin
arbitrary units, n  5–6/group). VEGFR2 activation, deter-
mined by phosphorylation of VEGFR2 on Tyr (951) (20,21)
was reduced by 50%, but not abolished, in Pod/sFlt-1 mice
treated with DOX (Fig. 2D).
VEGFR expression in glomerular cells. Immunogold
staining showed localization of VEGFR1 and VEGFR2 in
endothelial cells as previously reported. We detected
expression of VEGFR2, but not VEGFR1, in podocyte cell
body and foot processes in vivo (Fig. 3).
Clinical and biochemical features. There was no differ-
ence in creatinine clearance at 10 weeks (Pod/ VEH,
9.2 
 1.5; Pod/ DOX, 10.5 
 2.2; Pod/sFlt-1 VEH, 9.3 

1.6; Pod/sFlt-1 DOX, 10.6 
 1.7 l  min
1  g body wt
1,
n  6–9/group) and in albuminuria throughout the study
(n  10–12/group, geometric mean [95% CI] in g/24 h, at
baseline: Pod/ VEH, 22.3 [11.9–41.9]; Pod/ DOX, 23.9
[16.7–34.1]; Pod/sFlt-1 VEH, 33.3 [17.1–65.0]; and Pod/
sFlt-1 DOX, 28.1 [18.8–42.1]; at 10 weeks: Pod/ VEH, 20.6
[14–30.4]; Pod/ DOX, 22.7 [15.7–32.9]; Pod/sFlt-1 VEH,
28.4 [18.6–43]; and Pod/sFlt-1 DOX, 22.2 [14.1–34.8]).
Glomerular morphology was similar among the four
groups of animals (not shown). DOX administration did
not affect mice behaviors or body weight, which was
similar in all groups (not shown).
Role of podocyte sFlt-1 overexpression in diabetic
mice. In these experiments, only Pod/sFlt-1 mice were
studied. Mice were made diabetic at 5 weeks of age.
Treatment with VEH or DOX was started in 8-week-old
adult nondiabetic and diabetic Pod/sFlt-1 mice and
continued for up to 10 weeks (18 weeks of age). (Sexes
were pooled for analysis because they showed a similar
phenotype.)
Clinical and biochemical features. By the end of 10-
week DOX treatment, diabetic animals were lighter, had
raised blood pressure, and had higher creatinine clearance
than control animals. DOX did not affect any of these
variables in the nondiabetic and diabetic mice (Table 1).
Albumin excretion rate was similar at baseline in the
two diabetic (D) groups: D-VEH vs. D-DOX, geometric mean
(95% CI), in g/24 h, 28 (21–38) vs. 23 (14–36). By week 10
it had risen to 117.5 (69–199) in D-VEH, and this rise was
signiﬁcantly blunted in the D-DOX group overexpressing
sFlt-1: D-DOX, 43 (26.8–69) (P  0.003).
To obtain insight in the role of primary podocytes’ sFlt-1
overexpression in diabetes, we studied urine sFlt-1 and
free VEGF-A excretion, VEGF-A protein expression, and
VEGFR2 expression and phosphorylation in the renal
cortex lysate.
sFlt-1 and free VEGF-A 24-h urine excretion. Urine
sFlt-1 excretion was higher in VEH-administered diabetic
mice compared with VEH-administered nondiabetic ani-
mals (P  0.02). In the diabetic group, urine sFlt-1
excretion was signiﬁcantly higher in DOX-treated Pod/
sFlt-1 mice compared with VEH-administered animals
(D-VEH vs. D-DOX, 19.9 
 6.3 vs. 35 
 4.9 ng/24 h, P  0.03)
(Fig. 4A), a pattern similar to that seen in control nondia-
betic animals (Fig. 2A). Urine free VEGF-A 24 h excretion
was signiﬁcantly reduced after 10 weeks in DOX-treated
diabetic mice compared with VEH-administered diabetic
mice (P  0.04) (Fig. 4B).
VEGF-A expression, VEGFR2 expression, and phos-
phorylation in renal cortex. Renal cortex VEGF-A pro-
tein expression was signiﬁcantly upregulated as expected
A
C
B
GBM
GBM
FIG. 3. Expression of VEGFR1 and VEGFR2 in mouse glomerular cells.
Representative transmission electron microscopy images of VEGFR2
(A), VEGFR1 (B), and negative control (C). Immunogold staining
(arrows on black dots) in mouse glomerular capillaries. Positive
Immunogold staining is seen, as expected, in endothelial cells (EC) (A
and B) and, for the ﬁrst time, for VEGFR2 in podocyte cell body (P) and
foot processes (Pfp) (A). Scale bars represent 0.5 m.
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abetic VEH-administered mice (control [C]-VEH vs. D-VEH,
P  0.02); DOX treatment did not induce any change in
VEGF-A expression in diabetic mice (Fig. 5A).
VEGFR2 expression was upregulated in diabetic mice
by 80% (C-VEH vs. D-VEH, 100 
 16.7 vs. 178 
 11.7
VEGF-R2/-actin % change, n  5–6, P  0.01); DOX
treatment did not affect VEGFR2 expression in diabetic
mice (not shown). Similarly, VEGFR2 activation, deter-
mined as ratio of phosphorylation of VEGFR2 on Tyr (951)
over total VEGFR2 was increased by 60% in diabetic
mice (C-VEH vs. D-VEH, 100 
 15 vs. 158 
 10
VEGFR2
Tyr951/VEGFR2
tot % change, n  5–6, P  0.01);
DOX treatment was accompanied by a nonsigniﬁcant
decrease in VEGFR2 phosphorylation in diabetic mice
(Fig. 5B).
To further investigate the changes in albuminuria and to
examine the interaction between the VEGF-A/VEGF recep-
tor system and the TGF1 pathway in diabetic mice
treated with DOX, we studied nephrin, TGF1, and TGF-
receptor2 protein expression in renal cortex protein lysate
with Western immunoblotting.
Nephrin, TGF1, and TGF-receptor2 protein ex-
pression in renal cortex. Analysis of nephrin protein
expression in total renal cortex protein lysate resulted in
two bands at 196 and 200 kDa representing different
degrees of nephrin glycosylation (Fig. 6A) (22). Diabetic
VEH-administered animals had a higher level of nephrin
expression than nondiabetic control VEH-administered
mice (P  0.002). Treatment with DOX did not alter the
expression of nephrin in the diabetic and the nondiabetic
control mice.
TGF1 expression was upregulated in diabetic mice by
46% (C-VEH vs. D-VEH, 100 
 5.4 vs. 146 
 9.8 TGF1/-
actin % change, n  4–5, P  0.007). In diabetic mice,
treatment with DOX signiﬁcantly reduced TGF1 expres-
sion to virtually control levels (D-VEH vs. D-DOX, 146 
 9.8
vs. 104.7 
 4.5 TGF1/-actin % change, n  4–5, P 
0.001). DOX treatment did not change TGF1 expression
in nondiabetic control mice (Fig. 6B).
TGF-receptor2 protein expression was slightly but not
signiﬁcantly increased in diabetic mice. DOX treatment
did not affect its expression in nondiabetic and in diabetic
animals (not shown).
Mesangial area expansion. Mesangial volume fraction
(VvMes) was increased in VEH-administered diabetic mice
compared with VEH-administered control animals (C-VEH
vs. D-VEH, 0.16 
 0.1 vs. 0.22 
 0.01, P  0.003). Admin-
istration of DOX signiﬁcantly reduced VvMes in the dia-
betic mice (D-VEH vs. D-DOX, 0.22 
 0.01 vs. 0.18 
 0.01,
P  0.04) but had no effect in the control mice (C-VEH vs.
C-DOX, 0.16 
 0.01 vs. 0.17 
 0.01) (Fig. 7A and B).
GBM thickening, FPW, and endothelial fenestrae.
GBM thickness was signiﬁcantly increased in diabetic
mice compared with VEH-administered nondiabetic mice
(C-VEH vs. D-VEH, 176 
 8 vs. 219 
 8n m ,P  0.001).
Treatment with DOX ameliorated GBM thickening in dia-
betic mice (D-VEH vs. D-DOX, 219 
 8 vs. 197 
 7, P 
0.05) but had no signiﬁcant impact in nondiabetic control
animals (Fig. 8A and D).
FPW was increased in VEH-administered diabetic mice
compared with VEH-administered nondiabetic control an-
imals (C-VEH vs. D-VEH, 197 
 10 vs. 241 
 11 nm, P 
0.005). Treatment with DOX inducing sFlt-1 overexpres-
sion was paralleled by a reduction in FPW in diabetic mice
(D-VEH vs. D-DOX, 241 
 11 vs. 210 
 8, P  0.03) but had
no effect in nondiabetic control animals (Fig. 8B and D).
TABLE 1
Clinical and biochemical features in Pod/sFlt-1 nondiabetic control and diabetic mice treated with VEH or DOX for 10 weeks
Control
VEH
Control
DOX
Diabetic
VEH
Diabetic
DOX
Fed blood glucose (mmol/l) 7.1 
 1.1 6.2 
 1.0 26.08 
 1.6 27.4 
 1.8
Body weight (g) 28.4 
 2.3 28.0 
 1.8 21.1 
 2.3 22.3 
 0.7
Creatinine clearance (l  min
1  g
1) 9.3 
 1.6 10.6 
 1.7 14.9 
 2.9 14.5 
 3.6
Systolic blood pressure (mmHg) 106.1 
 5.0 107.1 
 4.8 122.8 
 4.9 124.0 
 4.9
Data are means 
 SEM. Diabetic mice were lighter than control mice. Systolic blood pressure and creatinine clearance were raised in the
diabetic mice. None of these variables were affected by DOX administration within the nondiabetic and diabetic groups (n  7–10/group).
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FIG. 4. Twenty four–hour urine sFlt-1 and free VEGF-A excretion in
diabetic podocyte-speciﬁc sFlt-1 overexpressing mice after 10 weeks of
treatment with VEH or DOX. A: VEH-treated diabetic mice had higher
urine sFlt-1 excretion than VEH-treated nondiabetic control mice
(*P  0.02 for C-VEH vs. D-VEH, n  6–10/group). Urine sFlt-1
excretion was signiﬁcantly higher in diabetic DOX-treated mice than in
diabetic VEH-treated animals (#P  0.03 for D-VEH vs. D-DOX, n 
7–10/group). B: In diabetic mice, urine free VEGF-A excretion was
signiﬁcantly reduced in DOX- vs. VEH-treated animals (#P  0.04 for
D-VEH vs. D-DOX, n  6–10/group).
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trated endothelium occupying the endothelial surface,
which was 53–57% and similar in the four groups of mice
studied (Fig. 8C and D).
DISCUSSION
VEGF-A appears to be critical for the maintenance of
capillary integrity, particularly in the glomerulus. In nor-
mal animals, systemic blockade of VEGF-A action is
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immunoblotting and densitometry quantitative analysis of renal cortex VEGF-A expression expressed as % change over nondiabetic VEH-treated
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VEH-treated mice. VEGFR2 phosphorylation was signiﬁcantly raised in diabetic VEH-treated mice by 58% over VEH-treated control animals (*P 
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expression, and proteinuria (6).
Moreover constitutive genetically mediated downregu-
lation of VEGF-A expression in podocytes leads to severe
impairment of glomerular function and glomerular endo-
thelial damage (5). Recent elegant studies in mice using an
inducible podocyte-speciﬁc system for site-speciﬁc VEGF
ablation resulted in glomerular barrier disruption, protein-
uria, and glomerular thrombotic microangiopathy mimick-
ing the proteinuria and glomerular damage seen in patients
receiving VEGF inhibitors, such as bevacizumav, for the
treatment of neoplastic disease (23). Concordantly, in
preeclampsia in humans, the greatly elevated circulating
levels of sFlt-1 are associated with proteinuria and glomer-
ular injury, suggesting that binding of sFlt-1 to VEGF may
impede its vasoprotective action at the capillary level
(18,24).
On the other hand, there are pathological conditions,
such as diabetes, in which the development of proteinuria
and glomerular pathology is associated with VEGF-A
overexpression in the podocytes. In the experimental
diabetic animal, systemic administration of VEGF inhibi-
tors, such as antibodies or chemicals, ameliorates protein-
uria and glomerular damage (8–10). These contrasting
situations suggest that both deﬁciency and excess of
VEGF may be detrimental to the physiological integrity of
glomerular capillaries.
In this study, we used an inducible expression system
that triggers VEGF-A inhibition after complete kidney
development (in the adult mouse). To achieve this, we
overexpressed, speciﬁcally in podocytes, the powerful
VEGF inhibitor sFlt-1 (11), thus avoiding systemic eleva-
tion of sFlt-1 levels, which, as seen in preeclampsia, may
disrupt the capillary wall (18). The system of podocyte-
speciﬁc conditional inhibition of VEGF-A thus circum-
vents the potentially important confounding effects on
renal glomerular development and aspeciﬁc VEGF inhibi-
tion in other tissues, which may have occurred with
previous experimental approaches.
Our ﬁndings demonstrated that in diabetes, tissue-spe-
ciﬁc inhibition of VEGF-A by excess sFlt-1 led to amelio-
ration of albuminuria and glomerulopathy, presumably by
blocking the molecular events mediated by diabetes-in-
duced VEGF overexpression.
sFlt-1 is a 110-kDa molecular weight protein that, under
physiological conditions, is not ﬁltered through the glo-
merular barrier. The podocyte-speciﬁc overexpression of
sFlt-1, which was induced in our system by the adminis-
tration of DOX (Fig. 1), would lead to a very localized
action of this molecule that within the podocyte would
sequester VEGF-A and inhibit its local autocrine and
paracrine effect as well as its migration toward the endo-
thelium and the mesangium.
The contention of autocrine and paracrine action of
podocyte-secreted VEGF is supported by the presence of
VEGF receptors in both endothelial and mesangial cells, as
previously reported (3,25), and by the detection for the
ﬁrst time in this work of VEGFR2 in mouse podocytes in
vivo. Both VEGFR1 And VEGFR2 are expressed in mouse
podocyte in vitro (4), but we were unable to detect
VEGFR1 in vivo; the discrepancy between the in vivo and
in vitro observations is probably attributable to the artiﬁ-
cial setting of the in vitro culture system, which can trigger
the induction of molecules normally not expressed in vivo
(3).
Supplementary proof of sFlt-1 podocyte overproduction
was provided by its signiﬁcantly increased 24-h urine
excretion and clear, though indirect, evidence of sFlt-1
inhibitory action by the marked reduction in urine free
VEGF-A excretion. This was true, though in different
degrees, for both nondiabetic and diabetic mice treated
with DOX, suggesting sequestration of VEGF-A.
In nondiabetic control mice, sFlt-1 overexpression–
induced inhibition of VEGF-A resulted in no glomerular
functional or morphological abnormalities. We believe
that the absence of structural and functional alterations
was probably explained by the upregulation of VEGF-A,
which occurred in the DOX-treated animals. This upregu-
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FIG. 7. Mesangial expansion in podocyte sFlt-1 overexpressing control
nondiabetic and diabetic mice after 10 weeks of treatment with VEH or
DOX. A: Quantitative electron microscopy of VvMes in control and
diabetic mice treated with VEH or DOX (n  6–8/group). VvMes was
increased in VEH-treated diabetic mice (*P  0.003 for C-VEH vs.
D-VEH). Treatment with DOX signiﬁcantly reduced VvMes in diabetic
mice (#P  0.04 for D-VEH vs. D-DOX) but had no effect in nondiabetic
control animals. B: Representative images on transmission electron
microscopy show amelioration of glomerular mesangial expansion in
DOX-treated diabetic mice compared with VEH-treated diabetic ani-
mals. Scale bars represent 5 m.
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rupted VEGF-A signaling because of sFlt-1 overexpression
and sequestration of VEGF-A. This might have mitigated
the effect of sFlt-1–mediated inhibition, and indeed free
VEGF-A in the urine, though reduced by 50%, was still
present in substantial amount and was paralleled by a still
present although reduced VEGFR2 activation/phosphory-
lation. This interpretation is supported by recent evidence
that suggests that in the adult mouse, full ablation of VEGF
is required to induce deﬁnite glomerular pathological
changes (23,26).
Diabetic mice developed the typical renal functional and
structural abnormalities of proteinuria, mesangial expan-
sion, GBM thickening, and podocyte foot process fusion.
These changes were associated with upregulation of
VEGF-A and VEGFR2 expression in renal cortex as previ-
ously described (25). Similar to nondiabetic mice, DOX-
induced sFlt-1 overexpression resulted in raised 24-h urine
excretion of sFlt-1 and signiﬁcant reduction (though not
abolition) of urine free VEGF-A excretion, suggesting
again “sequestration” of functional VEGF-A. Of interest,
24-h urine sFlt-1 excretion was higher in the diabetic mice
administered VEH compared with that in the control
nondiabetic mice receiving VEH, mimicking similar obser-
vations described in diabetic patients (17).
DOX-treated diabetic mice showed a modest nonsignif-
icant reduction in VEGFR2 phosphorylation compared
with VEH-administered animals. The higher degree of
glomerulosclerosis observed in VEH- versus DOX-treated
diabetic mice might explain this observation, as it has
been reported that VEGF receptor activation is inversely
related to the degree of glomerular injury (27). We focused
our work on VEGFR2 expression and phosphorylation
because VEGFR2, rather than VEGFR1, is involved in the
biological action of VEGF-A in adult animals (28,29) and is
overexpressed in experimental diabetes (25).
Inhibition of VEGF-A at the podocyte level in diabetic
mice improved the albuminuria and morphological
changes of the glomerular ﬁltration barrier by mitigating
GBM thickening and preventing foot process fusion and
also by markedly reducing mesangial matrix deposition.
This suggests the presence of a podocyte-podocyte as well
as a podocyte-mesangium cellular network, where podo-
cyte-speciﬁc gene expression can modulate the biology of
other subset of glomerular cells as previously suggested
for other podocyte secreted cytokines (13,23,26). Indeed
the sFlt-1 overexpression-induced amelioration of GBM
thickening and of mesangial extracellular matrix volume is
likely to result from an inhibition of the prosclerotic action
of VEGF-A (30,31), the reduction of TGF1 expression
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FIG. 8. GBM thickening, FPW, and endothelial fenestrae in podocyte sFlt-1 overexpressing control nondiabetic and diabetic mice after 10 weeks
of treatment with VEH or DOX. Quantitative electron microscopy determination of GBM thickening (A), podocyte FPW (B), and endothelial
fenestrae (C) in control and diabetic mice treated with VEH or DOX (n  7–8/group). GBM thickness (A) was higher in VEH-treated diabetic mice
vs. VEH-treated nondiabetic control animals (*P  0.001 for C-VEH vs. D-VEH). Administration of DOX reduced GBM thickness in diabetic mice
(#P  0.05 for D-VEH vs. D-DOX) but had no effect in nondiabetic mice. FPW (B) was increased in VEH-treated diabetic mice vs. VEH-treated
nondiabetic control animals (*P  0.005 for C-VEH vs. D-VEH). DOX administration ameliorated foot process fusion in diabetic mice (#P  0.03
for D-VEH vs. D-DOX), but no effect was seen in nondiabetic mice. The endothelial surface covered by endothelial fenestrae was not changed
within the four groups of animal studied (C). Representative images on transmission electron microscopy show amelioration of GBM thickening
and FPW in diabetic DOX-treated mice. Scale bars represent 2 m.
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and TGF1 is suggested by studies reporting a VEGF-A–
mediated TGF1 expression in mouse glomerular endo-
thelial cells (33).
Interestingly, in the diabetes sFlt-1 overexpressing mice,
no further upregulation of the already overexpressed
VEGF-A occurred, suggesting a “ceiling” for renal cortex
VEGF-A upregulation in the context of diabetes. In this
mouse model, neither diabetes nor the overexpression of
sFlt-1 altered the number of endothelial fenestrae in the
glomerular capillary.
Nephrin is a slit diaphragm protein whose deletion or
expression downregulation has been implicated in the
pathogenesis of proteinuria in diseases such as the con-
genital nephrotic syndrome of the Finnish type or in
minimal change nephrotic syndrome (34–36). In experi-
mental animal models of diabetes, nephrin expression has
been reported to be either upregulated or downregulated
(10,37–39). In our diabetic mice, nephrin was upregulated
when compared with control nondiabetic animals, and the
podocyte overexpression of sFlt-1 did not affect this
upregulation. These ﬁndings, in line with previous reports
(10), suggest that nephrin expression downregulation,
though it may be sufﬁcient, is not necessary for the
development of proteinuria and concur with the concept
that albuminuria may occur by a variety of mechanisms
such as redistribution of nephrin at the ultrastructural
level (10,40,41).
DOX, which was used in this study to induce sFlt-1
upregulation, is a nonselective inhibitor of metalloprotein-
ases (42,43), enzymes that regulate extracellular matrix
deposition, and may have confounded some of our ﬁnd-
ings. However, our present results in the nondiabetic
control mice and previous observations in normal animals
(13) and diabetic rodents (44) suggest no direct DOX-
mediated effects on albuminuria and extracellular matrix
at the dose used in this study. Moreover, DOX-induced
inhibition of metalloproteinases would favor matrix accu-
mulation and would result, if anything, in an underesti-
mate of the improvement in glomerular extracellular
matrix deposition in the podocyte sFlt-1 overexpressing
diabetic mice.
Our ﬁndings provide insight into the direct, local (auto-
crine/paracrine) role of VEGF-A in diabetes-induced glo-
merular injury, although the experimental design of this
work makes our results more relevant to the prevention
rather than treatment of diabetic glomerular damage.
Together with work by others (23), these ﬁndings support
the notion that in order to preserve vascular integrity, a
ﬁne balance in the regulation of VEGF-A expression is
required in as much as either too little or too much of this
cytokine would result in capillary vascular pathology.
These considerations highlight the potential pitfalls of
using systemic therapies to tackle tissue-speciﬁc changes.
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